Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder

Urologia Internationalis

Volumn 81, Issue 1, 2008, Pages 72-76

  Liu, LuCheng ^a   Zhu, DeChun ^a   Gao, RuiJuan ^b   Guo, Hang ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Angiogenesis; Kinase insert domain containing receptor; p53; Transitional cell carcinoma of the bladder; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; PARAFFIN; PROTEIN P53; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 47949099393     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137644     Document Type: Article

References (21)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-131.
2. Cunningham SA, Tran TM, Arrate MP: Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase: a real time kinetic study. J Biol Chem 1999;274:18421-18427.
3. Gakiopoulou-Givalou H, Nakopoulou L, Panayotopoulou EG: Non-endothelial KDR/flk-1 expression is associated with increased survival of patients with urothelial bladder carcinomas. Histopathology 2003;43:272-279.
4. Yagasaki H, Kawata N, Takimoto Y: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003;10:220-227.
5. Seto T, Higashiyama M, Funai H: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006;53:91-96.
6. Hoeben A, Landuyt B, Highley MS: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580.
7. Helmlinger G, Endo M, Ferrara N: Formation of endothelial cell networks. Nature 2000;405:139-141.
8. Vardar E, Gunlusoy B, Minareci S: Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder recurrence and progression. Urol Int 2006;77:27-33.
9. Yuan A, Yu CJ, Luh KT: Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 2002;20:900-910.
10. Giatromanolaki A, Koukourakis MI, Kakolyris S: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-3024.
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
12. Helmlinger G, Endo M, Ferrara N: Formation of endothelial cell networks. Nature 2000;405:139-141.
13. Wu W, Shu X, Hovsepyan H: VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-3370.
14. Weigand M, Hantel P, Kreienberg R: Autocrine vascular endothelial growth factor signaling in breast cancer: evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005;8:197-204.
15. Steiner HH, Karcher S, Mueller M: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neuro-Oncol 2004;66:129-138.
16. Perryman LA, Blair JM, Kinqsley EA: Overexpression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem Biophys Res Commun 2006;345:1207-1214.
17. Linderholm BK, Lindahl T, Holmberg L: The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-2260.
18. Reiher F, Ozer O, Pins M: p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002;167:1469-1474.
19. Inoue K, Slaton JW, Karashima T: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6:4866-4867.
20. Oshita F, Kameda Y, Hamanaka N: High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol 2004;27:215-219.
21. Ruifa H, Liwei L, Binxin L: Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Urol Int 2006;77:355-361.